bioMérieux
French company specialised in in vitro diagnostics
ISIN FR0010096479 LEI 549300AK8Y0LBIQ4T071
Follow bioMérieux
Weekly email: filings, results
Revenue, last year
€4.1B
+2.3% vs prior year
Net income
€397.5M
−8% vs prior year
EPS, diluted
-
Operating cash flow
€788.4M
+18.1% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €4.1B | €397.5M |
| FY24 | €4B | €432.2M |
| FY23 | €3.7B | €357.6M |
| FY22 | €3.6B | €452.4M |
| FY21 | €3.4B | €601.1M |
| FY20 | €3.1B | €404.4M |
| FY19 | €2.7B | €272.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 56.7% | 12.8% | 9.8% |
| FY24 | 55.7% | 14.8% | 10.9% |
| FY23 | 56% | 11.9% | 9.7% |
| FY22 | 56% | 16.4% | 12.6% |
| FY21 | 58.2% | 23.2% | 17.8% |
| FY20 | 56.2% | 17.7% | 13% |
| FY19 | 54.8% | 13.9% | 10.2% |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | €106.1M | €18.2M |
| FY24 | €100.2M | €37.6M |
| FY23 | €100.2M | €12.7M |
| FY22 | €101.2M | €157.2M |
| FY21 | €73.1M | €3.8M |
| FY20 | €22.5M | €18.4M |
| FY19 | €41.3M | €0 |